India plans new vaccines complex
This article was originally published in Scrip
India is setting up an integrated vaccines complex in Chengalpet near Chennai to manufacture a range of vaccines for use in its universal immunisation programme (UIP), and for export. The complex, being established by the public sector company Hindustan Latex, is expected to entail an investment of about Rs5 billion ($114.4 million).
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.